Springhill Fund Asset Management HK Co Ltd Invests $1.59 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)

Springhill Fund Asset Management HK Co Ltd purchased a new position in Janux Therapeutics, Inc. (NASDAQ:JANX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 29,600 shares of the company’s stock, valued at approximately $1,585,000. Janux Therapeutics comprises approximately 2.6% of Springhill Fund Asset Management HK Co Ltd’s holdings, making the stock its 15th largest position. Springhill Fund Asset Management HK Co Ltd owned 0.06% of Janux Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in JANX. Russell Investments Group Ltd. raised its holdings in Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after purchasing an additional 442 shares during the period. Rhumbline Advisers grew its position in shares of Janux Therapeutics by 1.6% in the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock valued at $2,043,000 after purchasing an additional 599 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in Janux Therapeutics by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company’s stock valued at $596,000 after buying an additional 1,095 shares in the last quarter. Virtu Financial LLC lifted its stake in Janux Therapeutics by 17.5% in the 4th quarter. Virtu Financial LLC now owns 8,769 shares of the company’s stock valued at $469,000 after buying an additional 1,306 shares in the last quarter. Finally, Avanza Fonder AB acquired a new stake in Janux Therapeutics in the 4th quarter worth about $139,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Janux Therapeutics

In related news, Director Ra Capital Management, L.P. bought 110,206 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was purchased at an average cost of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the acquisition, the director now owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. This trade represents a 1.10 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David Alan Campbell sold 5,000 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total value of $300,000.00. Following the sale, the chief executive officer now owns 293,054 shares in the company, valued at approximately $17,583,240. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,668 shares of company stock worth $548,183 over the last ninety days. Company insiders own 29.40% of the company’s stock.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock opened at $25.77 on Friday. Janux Therapeutics, Inc. has a fifty-two week low of $24.30 and a fifty-two week high of $71.71. The firm has a market capitalization of $1.52 billion, a price-to-earnings ratio of -22.03 and a beta of 3.27. The stock has a 50 day moving average of $34.09 and a 200 day moving average of $45.26.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on JANX. Scotiabank lowered their price target on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. Wedbush restated an “outperform” rating and issued a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Finally, Lifesci Capital upgraded Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Janux Therapeutics currently has an average rating of “Buy” and an average price target of $92.44.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.